193 related articles for article (PubMed ID: 30090877)
1. Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States.
Splawn LM; Bailey CA; Medina JP; Cho JC
Drugs Today (Barc); 2018 Jul; 54(7):399-405. PubMed ID: 30090877
[TBL] [Abstract][Full Text] [Related]
2. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease.
Kwon JY; Daoud ND; Hashash JG; Picco MF; Farraye FA
Inflamm Bowel Dis; 2023 Feb; 29(2):254-259. PubMed ID: 35468183
[TBL] [Abstract][Full Text] [Related]
5. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.
Hirst A; Hyer RN; Janssen RS
Vaccine; 2021 Jul; 39(33):4733-4741. PubMed ID: 34030898
[TBL] [Abstract][Full Text] [Related]
6. Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease.
Amjad W; Alukal J; Zhang T; Maheshwari A; Thuluvath PJ
Dig Dis Sci; 2021 Jun; 66(6):2101-2106. PubMed ID: 32617767
[TBL] [Abstract][Full Text] [Related]
7. Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV.
Khaimova R; Fischetti B; Cope R; Berkowitz L; Bakshi A
Vaccine; 2021 Oct; 39(44):6529-6534. PubMed ID: 34600748
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience.
Schnittman SR; Zepf R; Cocohoba J; Sears D
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):445-449. PubMed ID: 33196553
[TBL] [Abstract][Full Text] [Related]
9. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update.
Lee GH; Lim SG
Expert Rev Vaccines; 2021 May; 20(5):487-495. PubMed ID: 33783302
[No Abstract] [Full Text] [Related]
10. Hepatitis A and B Vaccination in the United States.
Sanchez MC
R I Med J (2013); 2020 Aug; 103(6):44-46. PubMed ID: 32752566
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults.
Mast EE; Weinbaum CM; Fiore AE; Alter MJ; Bell BP; Finelli L; Rodewald LE; Douglas JM; Janssen RS; Ward JW;
MMWR Recomm Rep; 2006 Dec; 55(RR-16):1-33; quiz CE1-4. PubMed ID: 17159833
[TBL] [Abstract][Full Text] [Related]
12. Preventing hepatitis B virus infection among healthcare professionals: potential impact of a 2-dose versus 3-dose vaccine.
Stevenson C; Youn JH; Hayney MS; David C
Hum Vaccin Immunother; 2021 Nov; 17(11):4567-4577. PubMed ID: 34505827
[TBL] [Abstract][Full Text] [Related]
13. A two-dose hepatitis B vaccine for adults (Heplisav-B).
Med Lett Drugs Ther; 2018 Jan; 60(1539):17-18. PubMed ID: 29364196
[No Abstract] [Full Text] [Related]
14. Adult immunization against hepatitis B: Does the number of jabs matter?
Oster G; Bornheimer R; Ottino K; Stevenson C; Lewin C; Janssen R
Vaccine; 2022 Jun; 40(26):3597-3604. PubMed ID: 35570079
[TBL] [Abstract][Full Text] [Related]
15. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant.
Schillie S; Harris A; Link-Gelles R; Romero J; Ward J; Nelson N
MMWR Morb Mortal Wkly Rep; 2018 Apr; 67(15):455-458. PubMed ID: 29672472
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
17. Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant.
Champion CR
Ann Pharmacother; 2021 Jun; 55(6):783-791. PubMed ID: 32988213
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China.
Zhu F; Deckx H; Roten R; Michiels B; Sarnecki M
Pediatr Infect Dis J; 2017 Jan; 36(1):94-101. PubMed ID: 27753794
[TBL] [Abstract][Full Text] [Related]
19. Surveillance for acute viral hepatitis - United States, 2007.
Daniels D; Grytdal S; Wasley A;
MMWR Surveill Summ; 2009 May; 58(3):1-27. PubMed ID: 19478727
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis.
Onuigbo MA; Nesbit A; Weisenbeck J; Hurlburt J
Ren Fail; 2010 May; 32(4):531-2. PubMed ID: 20446799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
